Cost‐effectiveness of second‐line empagliflozin versus liraglutide for type 2 diabetes in the United States-Reference-Cited by-同舟云学术

Cost‐effectiveness of second‐line empagliflozin versus liraglutide for type 2 diabetes in the United States

Published:2022-01-11 Issue: Volume: Page:
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Reifsnider Odette S.¹^ORCID,Pimple Pratik²,Brand Sarah¹^ORCID,Bergrath Washington Evelien³,Shetty Sharash²,Desai Nihar R.⁴

Affiliation:

1. Evidera Bethesda Maryland

2. Boehringer Ingelheim Pharmaceuticals Inc Ridgefield Connecticut

3. Evidera Waltham Massachusetts

4. Yale School of Medicine Cardiovascular Medicine New Haven Connecticut

Funder

Boehringer Ingelheim

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14625

Reference39 articles.

1. World Health OrganizationDiabetes Fact Sheet.https://www.who.int/news-room/fact-sheets/detail/diabetes.Published June 8 2020. Accessed August 7 2020.

2. Standards of medical care in diabetes‐2019 abridged for primary care providers;American Diabetes Association;Clin Diabetes.,2019

3. 2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution set Oversight Committee;Das SR;J Am Coll Cardiol.,2020

4. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman B;N Engl J Med.,2015

5. Liraglutide and cardiovascular outcomes in type 2 diabetes;Marso SP;N Engl J Med.,2016

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review;JBI Evidence Synthesis;2024-07-29

2. Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review;Advances in Therapy;2023-07-29

3. A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus;PharmacoEconomics;2023-07-06

4. Insight into continuous glucose monitoring: from medical basics to commercialized devices;Microchimica Acta;2023-04-06

5. Early type 2 diabetes treatment intensification with glucagon‐like peptide‐1 receptor agonists in primary care: An Australian perspective on guidelines and the global evidence;Diabetes, Obesity and Metabolism;2023-01-11